Clinical pharmacology of eptifibatide

American Journal of Cardiology

Volumn 80, Issue 4 A, 1997, Pages 11B-20B

  Phillips, David R ^a   Scarborough, Robert M ^a  

^a MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ANTITHROMBOCYTIC AGENT; CYCLOPEPTIDE; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; HEPTAPEPTIDE; PLACEBO; UNCLASSIFIED DRUG;

BLEEDING; CLINICAL TRIAL; CONFERENCE PAPER; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; NONHUMAN; PHARMACODYNAMICS; PHARMACOLOGY; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION INHIBITION; UNSTABLE ANGINA PECTORIS;

EID: 0030863733     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)00572-9     Document Type: Conference Paper

References (70)

1. Ambrose JA, Weinrauch M. Thrombosis in ischemic heart disease. Arch Intern Med. 156:1996;1382-1394.
2. Fuster V. Mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation. 90:1994;2126-2146.
3. Davies MJ. A macro and micro view of coronary vascular insult in ischemic heart disease. Circulation. 82:((suppl II)):1990;38-46.
4. Coller BS. Platelets in cardiovascular thrombosis and thrombolysis. Fozzard HA, Haber E, Jennings RB, Katz AM, Morgan HE. The Heart and Cardiovascular System. 2nd ed. 1992;219-273 Raven Press, New York.
5. Brunelli C, Spallarossa P, Rossettin P, Caponnetto S. Recognition and treatment of unstable angina. Drugs. 52:1996;196-208.
6. Coutré S, Leung L. Novel antithrombotic therapeutics targeted against platelet glycoprotein IIb/IIIa. Annu Rev Med. 46:1995;257-265.
7. Schafer AI. Antiplatelet therapy. Am J Med. 101:1996;199-209.
8. Landau C, Lange RA, Hillis LD. Percutaneous transluminal coronary angioplasty. N Engl J Med. 330:1994;981-993.
9. Ferguson JJ, Wilson JM. Early and late ischemic complications of PTCA. J Invas Cardiol. 6:((suppl A)):1994;3-12.
10. Almony GT, Lefkovits J, Topol EJ. Antiplatelet and anticoagulant use after myocardial infarction. Clin Cardiol. 19:1996;357-365.
11. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsch J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest. 86:1990;385-391.
12. Bunting S, Gryglewski R, Moncada S, Vane JR. Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac arteries and inhibits platelet aggregation. Prostaglandins. 12:1976;897-913.
13. Coller BS. Platelets and thrombolytic therapy. N Engl J Med. 322:1990;33-42.
14. Phillips DR, Charo IF, Parise LV, Fitzgerald LA. The platelet membrane glycoprotein IIb-IIIa complex. Blood. 71:1988;831-843.
15. Frishman WH, Burns B, Atac B, Alturk N, Altajar B, Lerrick K. Novel antiplatelet therapies for treatment of patients with ischemic heart disease: inhibitors of the platelet glycoprotein IIb/IIIa integrin receptor. Am Heart J. 130:1995;877-892.
16. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med. 332:1995;1553-1559.
17. Ohman EM, Harrington RA, Lincoff AM, Kitt MM, Kleiman NS, Tcheng JE. Early clinical experience with Integrelin, an inhibitor of the platelet glycoprotein IIb/IIIa integrin receptor. Eur Heart J. 16:((suppl L)):1995;50-55.
18. Tcheng JE, Harrington RA, Kottke-Marchant K, Kleiman NS, Ellis SG, Kereiakes DJ, Mick MJ, Navetta FI, Smith JE, Worley SJ, Miller JA, Joseph DM, Sigmon KN, Kitt MM, du Mée CP, Califf RM, Topol EJ. Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. Circulation. 91:1995;2151-2157.
19. Harrington RA, Kleiman NS, Kottke-Marchant K, Lincoff AM, Tcheng JE, Sigmon KN, Joseph D, Rios G, Trainor K, Rose D, Greenberg CS, Kitt MM, Topol EJ, Califf RM. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. Am J Cardiol. 76:1995;1222-1227.
20. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet. 349:1997;1422-1428.
21. Kieffer N, Phillips DR. Platelet membrane glycoproteins: functions in cellular interactions. Annu Rev Cell Biol. 6:1990;329-357.
22. Phillips DR, Charo IF, Scarborough RM. GPIIb-IIIa: the responsive integrin. Cell. 65:1991;359-362.
23. Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell. 69:1992;11-25.
24. Wagner CL, Mascelli MA, Neblock DS, Weisman HF, Coller BS, Jordan RE. Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets. Blood. 88:1996;907-914.
25. Jennings LK, Phillips DR. Purification of glycoproteins IIb and IIIa from human platelet plasma membranes and characterization of a calcium-dependent glycoprotein IIb-IIIa complex. J Biol Chem. 257:1982;10458-10466.
26. Rivas GA, González-Rodriguez J. Calcium binding to human platelet integrin GPIIb/IIIa and to its constituent glycoproteins. Effects of lipids and temperature. Biochem J. 276:1991;35-40.
27. Kunicki TJ, Pidard D, Rosa JP, Nurden AT. The formation of calcium-dependent complexes of platelet membrane glycoproteins IIb and IIIa in solution as determined by crossed immunoelectrophoresis. Blood. 58:1981;268-278.
28. Fitzgerald LA, Phillips DR. Calcium regulation of the platelet membrane glycoprotein IIb-IIIa complex. J Biol Chem. 260:1985;11366-11374.
29. Fujimura K, Phillips DR. Calcium cation regulation of glycoprotein IIb-IIIa complex formation in platelet plasma membranes. J Biol Chem. 258:1983;10247-10252.
30. Poncz M, Eisman R, Heidenreich R, Silver SM, Vilaire G, Surry S, Schwartz E, Bennett JS. Structure of the platelet membrane glycoprotein IIb: homology to the alpha subunits of the vitronectin and fibronectin membrane receptors. J Biol Chem. 262:1987;8476-8482.
31. Fitzgerald LA, Steiner B, Rall SC Jr, Lo S-S, Phillips DR. Protein sequence of endothelial glycoprotein IIIa derived from a cDNA clone: identity with platelet glycoprotein IIIa and similarity to "integrin." J Biol Chem. 262:1987;3936-3939.
32. Legrand C, Dubernard V, Nurden AT. Studies on the mechanism of expression of secreted fibrinogen on the surface of activated human platelets. Blood. 73:1989;1226-1234.
33. Law DA, Nannizzi-Alaimo L, Phillips DR. Outside-in integrin signal transduction. J Biol Chem. 271:1996;10811-10815.
34. 3 . EMBO J. 15:1996;5760-5771.
35. Ruoslahti E, Pierschbacher MD. Arg-Gly-Asp: a versatile cell recognition signal. Cell. 44:1986;517-518.
36. D'Souza SE, Ginsberg MH, Plow EF. Arginyl-glycyl-aspartic acid (RGD): a cell adhesion motif. Trends Biochem Sci. 16:1991;246-250.
37. Plow EF, Marguerie G, Ginsberg M. Fibrinogen, fibrinogen receptors, and the peptides that inhibit these interactions. Biochem Pharmacol. 36:1987;4035-4040.
38. Yamada T, Matsushima M, Inaka K, Ohkubo T, Uyeda A, Maeda T, Titani K, Sekiguchi K, Kikuchi M. Structural and functional analyses of the Arg-Gly-Asp sequence introduced into human lysozyme. J Biol Chem. 268:1993;10588-10592.
39. George JN, Caen JP, Nurden AT. Glanzmann's thrombasthenia: the spectrum of clinical disease. Blood. 75:1990;1383-1395.
40. Faulds D, Sorkin EM. Abciximab (c7E3 Fab): a review of its pharmacology and therapeutic potential in ischaemic heart disease. Drugs. 48:1994;583-598.
41. Coller BS, Peerschke EI, Scudder LE, Sullivan CA. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J Clin Invest. 72:1983;325-338.
42. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 330:1994;956-961.
43. Ferguson JJ. EPILOG and CAPTURE trials halted because of positive interim results. Circulation. 93:1996;637.
44. Tcheng JE. Platelet integrin glycoprotein IIb/IIIa inhibitors: opportunities and challenges. J Invas Cardiol. 8:((suppl B)):1996;8-14.
45. Coller BS, Scudder LE, Beer J, Gold HK, Folts JD, Cavagnaro J, Jordan R, Wagner C, Iuliucci J, Knight D, Ghrayeb J, Smith C, Weisman HF, Berger H. Monoclonal antibodies to platelet glycoprotein IIb/IIIa as antithrombotic agents. Ann NY Acad Sci. 614:1991;193-213.
46. Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S, Ivanhoe R, George BS, Fintel D, Weston M, Sigmon K, Anderson KM, Lee KL, Willerson JT. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet. 343:1994;881-886.
47. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 336:1997;1689-1696.
48. Kouns WC, Roux S, Steiner B. Human platelet GP IIb-IIIa receptor blockade as a therapeutic strategy. Curr Opin Invest Drugs. 2:1993;475-494.
49. Cook NS, Kottirsch G, Zerwes H-G. Platelet glycoprotein IIb/IIIa antagonists. Drugs of the Future. 19:1994;135-159.
50. Raddatz P, Gante J. Recent developments in glycoprotein IIb/IIIa antagonists. Exp Opin Ther Patients. 5:1995;1163-1183.
51. Schrör K. Antiplatelet drugs. A comparative review. Drugs. 50:1995;7-28.
52. Lefkovits J, Topol EJ. Platelet glycoprotein IIb/IIIa receptor antagonists in coronary artery disease. Eur Heart J. 17:1996;9-18.
53. Scarborough RM, Rose JW, Hsu MA, Phillips DR, Fried VA, Campbell AM, Nannizzi L, Charo IF. Barbourin: a GPIIb-IIIa-specific integrin antagonist from the venom of Sistrurus m. barbouri. J Biol Chem. 266:1991;9359-9362.
54. Scarborough RM, Rose JW, Naughton MA, Phillips DR, Nannizzi L, Arfsten A, Campbell AM, Charo IF. Characterization of the integrin specificities of disintegrins isolated from American pit viper venoms. J Biol Chem. 268:1993;1058-1065.
55. ++ on Integrilin GP IIb-IIIa interactions: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate. Circulation. In press.
56. Collen D, Lu HR, Stassen J-M, Vreys I, Yasuda T, Bunting S, Gold HK. Antithrombotic effects and bleeding time prolongation with synthetic platelet GPIIb/IIIa inhibitors in animal models of platelet-mediated thrombosis. Thromb Haemost. 71:1994;95-102.
57. Kleiman NS, Raizner AE, Jordan R, Wang AL, Norton D, Mace KF, Joshi A, Coller BS, Weisman HF. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin-receptor activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors. J Am Coll Cardiol. 26:1995;1665-1671.
58. Théroux P, Kouz S, Roy L, Knudtson ML, Diodati JG, Marquis J-F, Nasmith J, Fung AY, Boudreault JR, Delage F, Dupuis R, Kells C, Bokslag M, Steiner B, Rapold HJ. Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina. The Canadian lamifiban study. Circulation. 94:1996;899-905.
59. ++ accounts for the sex difference in the aggregation of human platelets in citrated platelet-rich plasma. Thromb Res. 58:1990;47-60.
60. Shattil SJ, Brass LF. The interaction of extracellular calcium with the platelet membrane glycoprotein IIb-IIIa complex. Nouv Rev Fr Hematol. 27:1985;211-217.
61. Marguerie GA, Edgington TS, Plow EF. Interaction of fibrinogen with its platelet receptor as part of a multistep reaction in ADP-induced platelet aggregation. J Biol Chem. 255:1980;154-161.
62. Scarborough RM, Naughton MA, Teng W, Hung DT, Rose J, Vu T-K H, Wheaton VI, Turck CW, Coughlin SR. Tethered ligand agonist peptides: structural requirements for thrombin receptor activation reveal mechanism of proteolytic unmasking of agonist function. J Biol Chem. 267:1992;13146-13149.
63. Hanson SR, Kotze HF, Savage B, Harker LA. Platelet interactions with Dacron vascular grafts: a model of acute thrombosis in baboons. Arteriosclerosis. 5:1985;595-603.
64. Uthoff K, Zehr KJ, Geerling R, Herskowitz A, Cameron DE, Reitz BA. Inhibition of platelet adhesion during cardiopulmonary bypass reduces postoperative bleeding. Circulation. 90:1994;269-274.
65. Charo IF, Scarborough RM, du Mée CP, Wolf D, Phillips DR, Swift RL. Pharmacodynamics of the GP IIb-IIIa antagonist Integrelin: Phase I clinical studies in normal healthy volunteers. (Abstr.). Circulation. 86:((suppl I)):1992;I-260.
66. Schulman SP, Goldschmidt-Clermont PJ, Topol EJ, Califf RM, Navetta FI, Willerson JT, Chandra NC, Guerci AD, Ferguson JJ, Harrington RA, Lincoff AM, Yakubov SJ, Bray PF, Bahr RD, Wolfe CL, Yock PG, Anderson HV, Nygard TW, Mason SJ, Effron MB, Fatterpacker A, Raskin S, Smith J, Brashears L, Gottdiener P, du Mee C, Kitt MM, Gerstenblith G. Effects of Integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina: a randomized multicenter trial. Circulation. 94:1996;2083-2089.
67. Ohman EM, Kleiman NS, Gacioch G, Worley SJ, Navetta FI, Talley JD, Anderson HV, Ellis SG, Cohen MD, Spriggs D, Miller M, Kereiakes D, Yakubov S, Kitt MM, Sigmon KN, Califf RM, Krucoff MW, Topol EJ. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction: results of a randomized, placebo-controlled, dose-ranging trial. Circulation. 95:1997;846-854.
68. Strony J, Hanson S. Personal communication.
69. Tcheng JE. Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective. Am J Cardiol. 78:((suppl 3A)):1996;35-40.
70. Harrington RA. Design and methodology of the PURSUIT Trial: Evaluating eptifibatide for acute ischemic coronary syndromes. Am J Cardiol. 80:((3B)):1997;34B-38B.